The internationalization industry of plant extract faces challenges and needs to enhance its competitiveness

<p><a href="https://www.pharmaceutical-sale.net/" rel="noopener noreferrer" target="_blank" style="color: rgb(4, 131, 74); background-color: transparent;"><a href="https://www.pharmaceutical-sale.net/" target="_blank">Plant extracts</a></a>&nbsp;industry in China is one of the areas are most likely to achieve internationalization of traditional Chinese medicine industry, but because do not have a unified standard, lack of the corresponding market regulators, it is difficult to form industry self-discipline and concentration, lead to many enterprises still stays in the category of chemical enterprises, and small scale as a whole, the international competitiveness is not strong, the future to be a power plant extract industry still has a long way to go.</p><p>&nbsp;</p><p>Against the background of the growing scale of global herbal medicine market, the global plant extract market continues to rise, forming the situation of the United States, Germany, Japan and France. The plant extract market in Germany has developed rapidly and has surpassed that in the United States. The sales volume of plant extract accounts for 22.68% of the world. The United States still maintains a large advantage, accounting for 22.21% of the total. Japan, which accounts for 19.75% of the global market size of plant extracts, is about to break through 20%. France accounts for 13.21%. With the rapid development in recent years, China is playing an increasingly important role in the world, with the market share of plant extracts reaching 7.16%. Driven by various aspects, the international competitiveness of China's plant extract industry is constantly improving.</p><p>&nbsp;</p><p>However, after the international financial crisis, Europe, the United States and Japan, the three major markets have shown a strong trend of localization, put forward new requirements on the price, cost and safety of extract products, And Chinese enterprises face challenges in the international market.</p><p>&nbsp;</p><p>A forum for the full Registration of Traditional Chinese Medicine in the European Union (EU) was held in Chengdu on March 23, hosted by multidimensional Evaluation Branch of World Federation of Chinese Medicine Societies and Chengdu University of Chinese Medicine. This is the first Chinese herbal extract standard with independent intellectual property rights to enter the pharmacopoeia of western countries, which represents an important achievement in the internationalization of Chinese traditional Medicine. Before that, there was no Chinese herbal extract standard with independent intellectual property right entering European pharmacopoeia. 373 alcohol saponins extract standard pharmacopeia for the first time in the western developed countries, it is not only a traditional Chinese medicine (TCM) full registered significant achievements in the process of the European Union, is also an important landmark in the internationalization of China's traditional Chinese medicine (TCM), a good interpretation of "standardization of traditional Chinese medicine (TCM) leading internationalization", make traditional Chinese medicine internationalization and boarded a new step.</p><p>&nbsp;</p><p>"If Chinese medicine products want to enter the EU, the basic course is to do a good job in the international standard system of Chinese medicinal materials, Chinese medicine extracts and Chinese patent medicine." Li Daning said notoginseng tong shu capsule is highly internationalized potential of modern traditional Chinese medicine, in a good international environment of Chinese medicine, should seize the opportunity, to 373 alcohol saponins API into the "German drug law" as an opportunity, efforts to promote the internationalization of product, enter the European market as soon as possible, to make greater contribution to the development of China's internationalization of Chinese medicine.</p><p>&nbsp;</p><p>In recent years, in order to promote the internationalization of Traditional Chinese medicine, the standardization of traditional Chinese medicine has been accelerated. Song Zonghua, director of the general business Department of the National Pharmacopoeia Commission, said that the inclusion of the standard in the German Drug Code proves that through continuous development and progress in recent years, the concept and thinking of Chinese traditional medicine standard research and the level of quality control have been more and more accepted and recognized by developed countries. "This is a new way for domestic TCM standards to go international and a solid step forward for TCM and TCM standards to go international."</p>